Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

921. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin (...) glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting Valentine W J, Palmer A J, Lammert M, Nicklasson L, Foos V, Roze S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of biphasic

2005 NHS Economic Evaluation Database.

922. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus

Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus Lechleitner M, Roden M, Haehling E (...) , Mueller M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of insulin glargine (IG) in combination with oral antidiabetic drugs (OADs) for the treatment of patients with Type 2 diabetes mellitus. Type of intervention Treatment

2005 NHS Economic Evaluation Database.

923. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK

Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Roze S, Valentine W J, Zakrzewska K E, Palmer A J (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study evaluated the use of continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) for the treatment of patients with Type 1 diabetes. Type

2005 NHS Economic Evaluation Database.

924. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966 - 2004)

Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966 - 2004) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

925. Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review

Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review Innes K E, Bourguignon C, Taylor A G CRD summary The review determined (...) the efficacy of yoga on anthropometric and physiologic indices of cardiovascular disease risk and related end points. Based on a large number of diverse primary studies of limited quality, the authors are justified in concluding that further well-conducted research is necessary. Authors' objectives To determine the efficacy of yoga on anthropometric and physiologic indices (such as insulin resistance syndrome, IRS) of cardiovascular disease (CVD) risk and on related end points. Searching MEDLINE, IndMED

2005 DARE.

926. Biphasic insulin aspart 30: literature review of adverse events associated with treatment

Biphasic insulin aspart 30: literature review of adverse events associated with treatment Biphasic insulin aspart 30: literature review of adverse events associated with treatment Biphasic insulin aspart 30: literature review of adverse events associated with treatment Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R CRD summary This review assessed the safety of biphasic insulin aspart 30 (BIAsp 30) for patients with diabetes. The authors concluded that the safety profile is comparable (...) to that of biphasic human insulin 30 (BHI 30) and neutral protamine Hagedorn (NPH) insulin, and that the risk of major and nocturnal hypoglycaemia is lower. Poor reporting and problems with review methodology mean that the reliability of these conclusions should be regarded with great caution. Authors' objectives To assess the safety of biphasic insulin aspart 30 (BIAsp 30), compared with alternative insulin products, in patients with type 1 or type 2 diabetes. Searching MEDLINE was searched to February 2005

2005 DARE.

927. Breath test for detection of insulin resistance (Diatest TM)

Breath test for detection of insulin resistance (Diatest TM) Breath test for detection of insulin resistance (Diatest TM) Breath test for detection of insulin resistance (Diatest TM) Topfer L-A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Topfer L-A. Breath test for detection of insulin resistance (Diatest TM) Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 Authors' objectives The aim of this study is to review the available information on the breath test for the detection of insulin resistance (Diatest TM) manufactured by Isodiagnostika Inc, Edmonton, AB. Authors' conclusions Breath tests are non-invasive, easily administered and more acceptable to patients than either blood or urine tests. Larger studies are needed to determine whether patients will benefit from the measurement of insulin

2005 Health Technology Assessment (HTA) Database.

928. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products

Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products Bullano M F, Al-Zakwani I S, Fisher M D, Menditto (...) L, Willey V J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two insulin products for the treatment of patients with Type 1 or Type 2 diabetes were examined. One was the intermediate-acting insulin analogue neutral protamine

2005 NHS Economic Evaluation Database.

929. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Full Text available with Trip Pro

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. Glucose-insulin-potassium (GIK) infusion is a widely applicable, low-cost therapy that has been postulated to improve mortality in patients with acute ST-segment elevation myocardial infarction (STEMI). Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine

2005 JAMA Controlled trial quality: predicted high

930. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. Full Text available with Trip Pro

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a phase 1 study. To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial (...) with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3).In a multicenter study, 80 patients with new-onset type 1 diabetes were randomly assigned to receive placebo or ChAglyCD3 for six consecutive days. Patients were followed for 18 months, during which their daily insulin needs and residual beta-cell function were assessed according to glucose-clamp-induced C-peptide release before and after the administration of glucagon.At 6, 12, and 18 months, residual beta-cell

2005 NEJM Controlled trial quality: uncertain

931. Diatest: point-of-care diagnostic test for detection of insulin resistance in patients at risk of Type 2 diabetes

Diatest: point-of-care diagnostic test for detection of insulin resistance in patients at risk of Type 2 diabetes National Horizon Scanning Unit Horizon scanning prioritising summary Volume 10, Number 3: Diatest ™ : Point-of-care diagnostic test for detection of insulin resistance in patients at risk of Type 2 diabetes. September 2005 © Commonwealth of Australia 2005 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining (...) summary was prepared by Adriana Parrella, Janet Hiller and Linda Mundy from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Department of Public Health, Mail Drop 511, University of Adelaide, South Australia, 5005. PRIORITISING SUMMARY REGISTER ID: 000172 NAME OF TECHNOLOGY: DIATEST ™ PURPOSE AND TARGET GROUP: POINT-OF-CARE DIAGNOSTIC TEST FOR DETECTION OF INSULIN RESISTANCE IN PATIENTS AT RISK OF TYPE 2 DIABETES. STAGE OF DEVELOPMENT (IN AUSTRALIA): ? Yet to emerge

2005 Australia and New Zealand Horizon Scanning Network

932. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. (Abstract)

"Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Adipose tissue expresses cytokines that inhibit insulin signalling pathways in liver and muscle. Obesity also results in impairment of endothelium-dependent vasodilatation in response to insulin. We propose a vasoregulatory role for local deposits of fat around the origin of arterioles supplying skeletal muscle. Isolated first-order arterioles from rat cremaster muscle are under dual (...) regulation by insulin, which activates both endothelin-1 mediated vasoconstriction and nitric-oxide-mediated vasodilatation. In obese rat arterioles, insulin-stimulated NO synthesis is impaired, resulting in unopposed vasoconstriction. We propose that this vasoconstriction is the consequence of production of the adipocytokine tumour necrosis factor alpha from the cuff of fat seen surrounding the origin of the arteriole in obese rats--a depot to which we ascribe a specialist vasoregulatory role. We

2005 Lancet

933. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. (Abstract)

Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Rising demand for islet transplantation will lead to severe donor shortage in the near future, especially in countries where cadaveric organ donation is scarce. We undertook a successful transplantation of living-donor islets for unstable diabetes. The recipient was a 27-year-old woman who had had brittle, insulin-dependent diabetes mellitus for 12 years. The donor, who was a healthy 56-year-old woman (...) and mother of the recipient, underwent a distal pancreatectomy. After isolation, 408 114 islet equivalents were transplanted immediately. The transplants functioned immediately and the recipient became insulin-independent 22 days after the operation. The donor had no complications and both women showed healthy glucose tolerance. Transplantation of living-donor islets from the distal pancreas can be sufficient to reverse brittle diabetes.

2005 Lancet

934. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. (Abstract)

Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Fast-food consumption has increased greatly in the USA during the past three decades. However, the effect of fast food on risk of obesity and type 2 diabetes has received little attention. We aimed to investigate the association between reported fast-food habits and changes in bodyweight and insulin resistance over a 15-year period in the USA.Participants for the CARDIA study included 3031 (...) young (age 18-30 years in 1985-86) black and white adults who were followed up with repeated dietary assessment. We used multiple linear regression models to investigate the association of frequency of fast-food restaurant visits (fast-food frequency) at baseline and follow-up with 15-year changes in bodyweight and the homoeostasis model (HOMA) for insulin resistance.Fast-food frequency was lowest for white women (about 1.3 times per week) compared with the other ethnic-sex groups (about twice

2005 Lancet

935. Endothelial inflammation in insulin resistance. (Abstract)

Endothelial inflammation in insulin resistance. Type 2 diabetes and attendant cardiovascular morbidity are becoming major health concerns globally. Obesity-related type 2 diabetes is rapidly rising in prevalence, probably largely because of increased longevity and sedentary lifestyles. Insulin resistance and type 2 diabetes are associated with increased coronary heart disease, but the severity of glycaemia during the diabetic phase can only to a minor extent explain the increased risk (...) . Increased levels of the acute-phase inflammatory marker, C-reactive protein (CRP), are related to insulin resistance and the metabolic syndrome, suggesting a role for chronic low-grade inflammation. CRP levels might predict the development of type 2 diabetes.Subodh Verma and associates (Circulation 2004; 109: 2058-67) recently showed that CRP attenuates the survival, differentiation, and function of endothelial progenitor cells, partly by CRP reducing expression of endothelial nitric-oxide synthase

2005 Lancet

936. insulin glargine (rDNA origin)

insulin glargine (rDNA origin) CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION INSULIN GLARGINE (Lantus® - Aventis Pharma Inc.) Description: Insulin glargine is an insulin analog indicated for once-daily subcutaneous administration for patients over 17 years of age with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends (...) that insulin glargine not be listed. Dosage Forms: 100 IU/mL, 10 mL vial Reasons for the recommendation: 1. The committee considered 20 open-label randomized controlled trials (RCTs) lasting from 4 to 52 weeks that compared insulin glargine with NPH insulin, of which 11 were conducted in Type 1 diabetes and 9 in Type 2 diabetes. One trial compared insulin glargine with insulin ultralente in Type 1 diabetes. The studies did not find statistically or clinically significant differences between insulin

2005 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

937. Premature birth and later insulin resistance. (Abstract)

Premature birth and later insulin resistance. Term infants who are small for gestational age appear prone to the development of insulin resistance during childhood. We hypothesized that insulin resistance, a marker of type 2 diabetes mellitus, would be prevalent among children who had been born prematurely, irrespective of whether they were appropriate for gestational age or small for gestational age.Seventy-two healthy prepubertal children 4 to 10 years of age were studied: 50 who had been (...) born prematurely (32 weeks' gestation or less), including 38 with a birth weight that was appropriate for gestational age (above the 10th percentile) and 12 with a birth weight that was low (i.e., who were small) for gestational age, and 22 control subjects (at least 37 weeks' gestation, with a birth weight above the 10th percentile). Insulin sensitivity was measured with the use of paired insulin and glucose data obtained by frequent measurements during intravenous glucose-tolerance tests.Children

2004 NEJM

938. Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes Full Text available with Trip Pro

Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Training in flexible intensive insulin management improved glycaemic control and quality of life in type 1 diabetes Article Text Treatment Training in flexible

2004 Evidence-Based Nursing

939. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. (Abstract)

Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. Liposuction has been proposed as a potential treatment for the metabolic complications of obesity. We evaluated the effect of large-volume abdominal liposuction on metabolic risk factors for coronary heart disease in women with abdominal obesity.We evaluated the insulin sensitivity of liver, skeletal muscle, and adipose tissue (with a euglycemic-hyperinsulinemic clamp procedure and isotope-tracer (...) with normal oral glucose tolerance lost 9.1+/-3.7 kg of fat (18+/-3 percent decrease in total fat, P=0.002), and those with type 2 diabetes lost 10.5+/-3.3 kg of fat (19+/-2 percent decrease in total fat, P<0.001). Liposuction did not significantly alter the insulin sensitivity of muscle, liver, or adipose tissue (assessed by the stimulation of glucose disposal, the suppression of glucose production, and the suppression of lipolysis, respectively); did not significantly alter plasma concentrations of C

2004 NEJM

940. Best practice guideline for the subcutaneous administration of insulin in adults with type 2 diabetes.

Best practice guideline for the subcutaneous administration of insulin in adults with type 2 diabetes. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines

2004 Registered Nurses' Association of Ontario